VRNA
Income statement / Annual
Last year (2024), Verona Pharma plc's total revenue was $33.77 M,
and the percentage change from the previous year is not available.
In 2024, Verona Pharma plc's net income was -$138.52 M.
See Verona Pharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$33.77 M |
$0.00 |
$378.87 K |
$29.58 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.06 M
|
$0.00
|
$286.22 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$31.71 M
|
$0.00
|
$92.65 K
|
$29.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.94
|
0
|
0.24
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$35.60 M
|
$13.50 M
|
$40.77 M
|
$58.72 M
|
$32.54 M
|
$32.02 M
|
$19.29 M
|
$23.72 M
|
$4.52 M
|
$7.27 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$7.20 M
|
$11.66 M
|
$29.77 M
|
$8.99 M
|
$7.99 M
|
$8.10 M
|
$2.89 M
|
$2.51 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$19.38 M
|
$22.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$119.61 M
|
$39.50 M
|
$21.99 M
|
$25.07 M
|
$21.77 M
|
$7.54 M
|
$6.30 M
|
$6.04 M
|
$2.50 M
|
$1.71 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$155.21 M
|
$53.00 M
|
$62.75 M
|
$83.79 M
|
$54.32 M
|
$39.56 M
|
$25.59 M
|
$29.76 M
|
$7.02 M
|
$8.98 M
|
| Cost And Expenses |
$157.28 M
|
$53.00 M
|
$63.04 M
|
$83.79 M
|
$54.32 M
|
$39.56 M
|
$25.59 M
|
$29.76 M
|
$7.02 M
|
$8.98 M
|
| Interest Income |
$15.26 M
|
$12.81 M
|
$2.82 M
|
$14.00 K
|
$121.00 K
|
$988.62 K
|
$1.09 M
|
$466.24 K
|
$106.78 K
|
$66.36 K
|
| Interest Expense |
$23.54 M
|
$2.06 M
|
$521.00 K
|
$340.00 K
|
$35.00 K
|
$221.59 K
|
$0.00
|
$98.65 K
|
$104.52 K
|
$0.00
|
| Depreciation & Amortization |
$845.07 K
|
$531.06 K
|
$526.11 K
|
$465.13 K
|
$455.57 K
|
$384.99 K
|
$93.00 K
|
$118.00 K
|
$61.00 K
|
$53.00 K
|
| EBITDA |
-$119.79 M |
-$51.61 M |
-$54.17 M |
-$42.19 M |
-$47.81 M |
-$32.17 M |
-$25.50 M |
-$29.64 M |
-$6.96 M |
-$8.92 M |
| EBITDA Ratio |
-3.55
|
0
|
-142.97
|
-1.43
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-3.66
|
0
|
-165.39
|
-1.83
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.79 M
|
$10.73 M
|
$6.04 M
|
$13.11 M
|
$6.78 M
|
$8.99 M
|
$1.46 M
|
$4.55 M
|
$1.05 M
|
-$28.00 K
|
| Income Before Tax |
-$130.30 M
|
-$42.28 M
|
-$56.62 M
|
-$41.10 M
|
-$47.53 M
|
-$30.56 M
|
-$24.13 M
|
-$25.20 M
|
-$5.97 M
|
-$9.00 M
|
| Income Before Tax Ratio |
-3.86
|
0
|
-149.45
|
-1.39
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$8.22 M
|
$371.82 K
|
$209.29 K
|
-$13.31 K
|
$106.76 K
|
$54.35 K
|
-$4.23 M
|
-$4.71 M
|
-$954.00 K
|
-$1.51 M
|
| Net Income |
-$138.52 M
|
-$42.65 M
|
-$56.83 M
|
-$41.09 M
|
-$47.64 M
|
-$30.62 M
|
-$19.90 M
|
-$20.50 M
|
-$5.02 M
|
-$7.50 M
|
| Net Income Ratio |
-4.1
|
0
|
-150
|
-1.39
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.7 |
-0.54 |
-0.86 |
-0.69 |
-1.45 |
-2.33 |
-1.51 |
-1.87 |
-1.2 |
-2.97 |
| EPS Diluted |
-1.73 |
-0.56 |
-0.86 |
-0.69 |
-1.45 |
-2.33 |
-1.51 |
-1.87 |
-1.2 |
-2.97 |
| Weighted Average Shares Out |
$80.29 M
|
$75.51 M
|
$66.06 M
|
$59.15 M
|
$32.87 M
|
$13.17 M
|
$13.14 M
|
$10.97 M
|
$4.19 M
|
$2.52 M
|
| Weighted Average Shares Out Diluted |
$81.54 M
|
$79.27 M
|
$66.13 M
|
$59.15 M
|
$32.87 M
|
$13.17 M
|
$13.14 M
|
$10.97 M
|
$4.19 M
|
$2.52 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
